Shaanxi Kanghui Pharm Co Ltd (SHG:603139) — Market Cap & Net Worth
Market Cap & Net Worth: Shaanxi Kanghui Pharm Co Ltd (603139)
Shaanxi Kanghui Pharm Co Ltd (SHG:603139) has a market capitalization of $554.37 Million (CN¥3.79 Billion) as of September 21, 2026. Listed on the SHG stock exchange, this China-based company holds position #11816 globally and #3388 in its home market, demonstrating a -2.64% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shaanxi Kanghui Pharm Co Ltd's stock price CN¥37.93 by its total outstanding shares 99880000 (99.88 Million). Also see 603139 current and non-current assets for a full breakdown of the balance sheet.
Shaanxi Kanghui Pharm Co Ltd Market Cap History: 2017 to 2026
Shaanxi Kanghui Pharm Co Ltd's market capitalization history from 2017 to 2026. Data shows growth from $355.94 Million to $554.37 Million (6.81% CAGR). Also see Shaanxi Kanghui Pharm Co Ltd (603139) cash conversion ratio for how efficiently the company converts equity into cash flow.
Shaanxi Kanghui Pharm Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Shaanxi Kanghui Pharm Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check 603139 stock price and chart for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.63x
Shaanxi Kanghui Pharm Co Ltd's market cap is 0.63 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $355.94 Million | $367.06 Million | $63.02 Million | 0.97x | 5.65x |
| 2018 | $221.31 Million | $375.62 Million | $55.63 Million | 0.59x | 3.98x |
| 2019 | $248.64 Million | $431.42 Million | $42.76 Million | 0.58x | 5.81x |
| 2020 | $243.33 Million | $414.07 Million | $34.11 Million | 0.59x | 7.13x |
| 2021 | $317.00 Million | $442.76 Million | $36.48 Million | 0.72x | 8.69x |
| 2022 | $259.43 Million | $491.51 Million | -$63.06 Million | 0.53x | N/A |
| 2023 | $274.33 Million | $672.96 Million | -$26.16 Million | 0.41x | N/A |
| 2024 | $209.88 Million | $561.63 Million | -$89.63 Million | 0.37x | N/A |
| 2025 | $299.18 Million | $471.29 Million | -$333.45 Million | 0.63x | N/A |
Competitor Companies of 603139 by Market Capitalization
Companies near Shaanxi Kanghui Pharm Co Ltd in the global market cap rankings as of September 21, 2026. Review Shaanxi Kanghui Pharm Co Ltd tangible equity quality to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Shaanxi Kanghui Pharm Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #612 globally with a market cap of $44.88 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #670 globally with a market cap of $40.99 Billion USD ( CN¥280.10 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #612 | GALDERMA GROUP AG | NYSE:GALDY | $44.88 Billion | $38.49 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.90 |
| #670 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $40.99 Billion | CN¥43.91 |
Shaanxi Kanghui Pharm Co Ltd Historical Marketcap From 2017 to 2026
Between 2017 and today, Shaanxi Kanghui Pharm Co Ltd's market cap moved from $355.94 Million to $ 554.37 Million, with a yearly change of 6.81%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥554.37 Million | +85.30% |
| 2025 | CN¥299.18 Million | +42.55% |
| 2024 | CN¥209.88 Million | -23.49% |
| 2023 | CN¥274.33 Million | +5.75% |
| 2022 | CN¥259.43 Million | -18.16% |
| 2021 | CN¥317.00 Million | +30.27% |
| 2020 | CN¥243.33 Million | -2.13% |
| 2019 | CN¥248.64 Million | +12.35% |
| 2018 | CN¥221.31 Million | -37.82% |
| 2017 | CN¥355.94 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 21st, 2026 the market cap of Shaanxi Kanghui Pharm Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $554.37 Million USD |
| MoneyControl | $554.37 Million USD |
| MarketWatch | $554.37 Million USD |
| marketcap.company | $554.37 Million USD |
| Reuters | $554.37 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Shaanxi Kanghui Pharm Co Ltd
Shaanxi Kanghui Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical intermediates in China. It is involved in the research, development, production, and sale of traditional Chinese medicine preparations; research and development of prepared slices of Chinese medicinal herbs and pharmaceutical intermediates; and pharmaceutical distribution of biolo… Read more